Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: report of seven cases and literature review

Silva, Leonardo Sales da; Campos, Karla Valéria Miranda de; Melo, Ana Karla Guedes de; Brito, Danielle Christinne Soares Egypto de; Braz, Alessandra de Sousa; Freire, Eutília Andrade Medeiros

doi:10.1016/j.rbre.2015.07.016

Cited by 3 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of rituximab was also reported in isolated cutaneous PAN with satisfying results [ 9 ]. Reports similar to ours detailing the efficacy of rituximab in the treatment of refractory PAN are compiled in Table 1 [ 3 , 7 - 11 ]. However, it is important to note that cases of rituximab resistance in refractory PAN were also reported [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of rituximab in refractory polyarteritis nodosa: a case report

Boukhris,

Hamdi,

Hariz

et al. 2023

Pan Afr Med J

View full text Add to dashboard Cite

Polyarteritis nodosa (PAN) is a systemic vasculitis affecting medium and small-sized vessels resulting in multiple organ involvement. Refractory PAN requires a different therapeutic approach. We herein report the case of a 42-year-old male presenting a non-virus-related refractory PAN with a favorable outcome on rituximab. He presented significant weight loss, muscle weakness, peripheral axonal neuropathy, and medium-sized cutaneous vessel necrotizing vasculitis. The patient received high-dose corticosteroids and cyclophosphamide with no significant clinical improvement while developing adverse side effects such as hypertension and diabetes. Rituximab was prescribed as an alternative therapy at 1000 mg on day 0 and day 15. This allowed for complete and rapid control of disease activity with regression of cutaneous injury and substantial improvement of neurological symptoms. In conclusion, using chimeric anti-CD20 monoclonal antibodies, such as rituximab, although rarely reported in refractory non-virus-related PAN, may be an effective alternative therapy, as portrayed in our case.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of rituximab in refractory polyarteritis nodosa: a case report

Boukhris,

Hamdi,

Hariz

et al. 2023

Pan Afr Med J

View full text Add to dashboard Cite

show abstract

“…Rituximab is not available at our service, but some other services use it to treat this disease. 21 The countless publications on vasculitis in the literature are unanimous on the high complexity of etiologic investigation, causing excessive delays, elevated costs and delayed treatment. 1,7 The case of CLV described here illustrates how treatment success is dependent on rapid diagnostic investigation and early treatment.…”

Section: Discussionmentioning

confidence: 99%

Diagnóstico e terapêutica precoce de vasculite leucocitoclástica: relato de caso

et al. 2020

View full text Add to dashboard Cite

Resumo Paciente do sexo feminino, 46 anos de idade, procurou o pronto socorro do Hospital Municipal Universitário apresentando lesões necróticas em membros inferiores associadas à síndrome consumptiva. Após anamnese e exame físico, obteve-se o diagnóstico de vasculite leucocitoclástica de modo imediato e econômico por meio da utilização de algoritmo específico de vasculites primárias, permitindo início precoce da terapêutica adequada. A boa evolução do quadro clínico ratificou a necessidade de se obter diagnóstico definitivo e início rápido da terapêutica.

show abstract

“…Other cases utilized alternative regimens of rituximab and included several pediatric cPAN patients [ 174 , 175 ]. Rituximab has also proven to be useful in the rare subset of viral-associated PAN patients with HBV or HCV [ 176 , 177 ]. Additional studies following rituximab usage in PAN provided mixed results [ 173 , 178 – 180 ], and the most recent papers have shown anti-CD20 therapy to be ineffective in several patients [ 181 – 184 ].…”

Section: Rituximab In Dermatologic Conditionsmentioning

confidence: 99%

Off-Label Uses of Rituximab in Dermatology

Cole

Amber

2022

Curr Derm Rep

View full text Add to dashboard Cite

Purpose of Review Rituximab has transformed the treatment of B-cell malignancies and rheumatoid arthritis in the past 2 decades. More recently, this anti-CD20 monoclonal antibody has seen increasing usage in the field of dermatology. This review highlights the evidence supporting its use in several important dermatologic conditions. Recent Findings Key recent findings include the 2018 FDA approval of rituximab for the treatment of moderate-to-severe pemphigus. Summary Data from randomized controlled trials have demonstrated the efficacy of rituximab in pemphigus, ANCA-associated vasculitis, and cryoglobulinemic vasculitis. More limited data suggests its use in recalcitrant cases of diseases such as pemphigoid, epidermolysis bullosa acquisita, and dermatomyositis. There is scarce evidence and mixed results for rituximab when studied in cutaneous polyarteritis nodosa and cutaneous lupus erythematosus.

show abstract

Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: report of seven cases and literature review

Cited by 3 publications

References 14 publications

Efficacy of rituximab in refractory polyarteritis nodosa: a case report

Efficacy of rituximab in refractory polyarteritis nodosa: a case report

Diagnóstico e terapêutica precoce de vasculite leucocitoclástica: relato de caso

Off-Label Uses of Rituximab in Dermatology

Contact Info

Product

Resources

About